152 related articles for article (PubMed ID: 23043499)
1. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Wilgenhof S; Du Four S; Everaert H; Neyns B
Cancer Invest; 2012 Dec; 30(10):712-20. PubMed ID: 23043499
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
[TBL] [Abstract][Full Text] [Related]
4. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Berrocal A; Arance A; Lopez Martin JA; Soriano V; Muñoz E; Alonso L; Espinosa E; Lopez Criado P; Valdivia J; Martin Algarra S;
Melanoma Res; 2014 Dec; 24(6):577-83. PubMed ID: 25046550
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
Altomonte M; Di Giacomo A; Queirolo P; Ascierto P; Spagnolo F; Bajetta E; Calabrò L; Danielli R; de Rosa F; Maur M; Chiarion-Sileni V; Ferrucci P; Giannarelli D; Testori A; Ridolfi R; Maio M
J Exp Clin Cancer Res; 2013 Oct; 32(1):82. PubMed ID: 24423086
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS; Qian W; Ellis S; Mason E; Khattak MA; Gupta A; Shaw H; Quinton A; Kovarikova J; Thillai K; Rao A; Board R; Nobes J; Dalgleish A; Grumett S; Maraveyas A; Danson S; Talbot T; Harries M; Marples M; Plummer R; Kumar S; Nathan P; Middleton MR; Larkin J; Lorigan P; Wheater M; Ottensmeier CH; Corrie PG
Melanoma Res; 2015 Oct; 25(5):432-42. PubMed ID: 26225580
[TBL] [Abstract][Full Text] [Related]
8. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
[TBL] [Abstract][Full Text] [Related]
9. The ipilimumab lesson in melanoma: achieving long-term survival.
Delyon J; Maio M; Lebbé C
Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
11. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Wilgenhof S; Du Four S; Vandenbroucke F; Everaert H; Salmon I; Liénard D; Marmol VD; Neyns B
J Immunother; 2013 Apr; 36(3):215-22. PubMed ID: 23502769
[TBL] [Abstract][Full Text] [Related]
12. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
13. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
14. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M; Mellor JD; McArthur G; Kee D
Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
[TBL] [Abstract][Full Text] [Related]
16. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
17. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
18. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA; Simeone E; Sileni VC; Pigozzo J; Maio M; Altomonte M; Del Vecchio M; Di Guardo L; Marchetti P; Ridolfi R; Cognetti F; Testori A; Bernengo MG; Guida M; Marconcini R; Mandalà M; Cimminiello C; Rinaldi G; Aglietta M; Queirolo P
J Transl Med; 2014 May; 12():116. PubMed ID: 24885479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
